It was used by the United States military from 1971 to 1999, but was discontinued when the only manufacturer stopped production. This vaccine elicited immunity to serotypes 4 and 7. On March 16, 2011, the U.S. Food and Drug Administration approved an adenovirus vaccine manufactured by Teva Pharmaceuticals under contract to the U.S. Army. This vaccine is essentially the same as the one used from 1971 to 1999. On October 24, 2011 the military services began administering the new adenovirus vaccine to recruits during basic training. In its first year of use, adenovirus vaccine prevented 15,000 cases of Febrile Respiratory Illness, as evidenced by a reduction in the rate of Febrile Respiratory Illness that began soon after October 2011.
It should not be confused with the strategy of using adenovirus as a carrier to develop vaccines for other pathogens, or as a general gene carrier.
^Centers for Disease Control and Prevention (CDC) (July 2001). "Two fatal cases of adenovirus-related illness in previously healthy young adults--Illinois, 2000". MMWR Morb. Mortal. Wkly. Rep.50 (26): 553–5. PMID11456329.
^Malarkey MA, Baylor NW. FDA approval letter dated March 16, 2011.